Meeting
2019 Gastrointestinal Cancers Symposium
An analysis of the safety and efficacy of rivaroxaban (Riv) and low molecular weight heparin (LMWH) in gastrointestinal cancer-associated venous thromboembolism (GICA-VTE).
Authors
Alejandro Recio Boiles
University of Arizona Cancer Center, Tucson, AZ
Alejandro Recio Boiles , Sumana Veeravelli , Jessi Vondrak , Hani M. Babiker , Aaron James Scott , Ali McBride , Emad Elquza
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 37, 2019 (suppl 4; abstr 374)
DOI
10.1200/JCO.2019.37.4_suppl.374
Abstract #
374
Poster Bd #
K14
Abstract Disclosures
Similar Posters
Poster
2018 Gastrointestinal Cancers Symposium
An analysis of the efficacy and safety of direct oral anticoagulants (DOACs) in gastrointestinal cancer-associated venous thromboembolism (GI-CAVTE).
First Author: Alejandro Recio Boiles
Poster
2022 ASCO Annual Meeting
Real-world utilization and comparative effectiveness of treatment options in cancer-associated thrombosis: A propensity score weighed analysis.
First Author: Irbaz Bin Riaz
Poster
2021 Genitourinary Cancers Symposium
A retrospective real-world major bleeding (MB) comparison of direct oral anticoagulants (DOAC) and low molecular weight heparin (LMWH) in genitourinary cancer-associated venous thromboembolism (GU-CAVTE) with reported randomized clinical trials (RTC).
First Author: Ulyana Dashkevych
Poster
2020 ASCO Virtual Scientific Program
Efficacy and safety of direct oral anticoagulants (DOACs) and low molecular weight heparin (LMWH) for primary prevention of venous thromboembolism (VTE) in ambulatory cancer patients.
First Author: Mina Shenouda